A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|121|19|3481-3490

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.19, 2015-10, pp. : 3481-3490

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma

By Hollebecque A.   Deutsch E.   Massard C.   Gomez-Roca C.   Bahleda R.   Ribrag V.   Bourgier C.   Lazar V.   Lacroix L.   Gazzah A.   Varga A.   Baere T.   Beier F.   Kroesser S.   Trang K.   Zenke F.   Klevesath M.   Soria Jean-Charles  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1530-1538

Springer Publishing Company

Access to resources Recommend Favorite

A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors

By Traynor Anne   Gordon Michael   Alberti Dona   Mendelson David   Munsey Mark   Wilding George   Gammans Richard   Read William  

Investigational New Drugs, Vol. 28, Iss. 4, 2010-08 ,pp. : 509-515

Springer Publishing Company

Access to resources Recommend Favorite

Safety, tolerability and pharmacokinetics of 2‐pyridylacetic acid, a major metabolite of betahistine, in a phase 1 dose escalation study in subjects with ADHD

By  

Biopharmaceutics And Drug Disposition, Vol. 36, Iss. 7, 2015-10 ,pp. : 429-439

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study

By Blais Normand   Camidge D.   Jonker Derek   Soulières Denis   Laurie Scott   Diab Sami   Ruiz-Garcia Ana   Thall Aron   Zhang Ke   Chao Richard   Chow Laura  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1487-1498

Springer Publishing Company

Access to resources Recommend Favorite

A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers

By Goel Sanjay   Desai Kavita   Macapinlac Manuel   Wadler Scott   Goldberg Gary   Fields Abbie   Einstein Mark   Volterra Fabio   Wong Benny   Martin Russell   Mani Sridhar  

Investigational New Drugs, Vol. 24, Iss. 2, 2006-03 ,pp. : 125-134

Springer Publishing Company

Access to resources Recommend Favorite